Status:

COMPLETED

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Lead Sponsor:

Abbott

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab ...

Detailed Description

The objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy. The study is a...

Eligibility Criteria

Inclusion

  • Subject \> 18 years of age
  • Subject has a diagnosis of RA as defined by the 1987-revised ACR-classification criteria and has a disease duration for a minimum of three months
  • Subject must meet the following two criteria: a) At least 6 swollen joints out of 66 assessed, or b) At least 6 tender joints out of 68 assessed
  • If a subject is on MTX, the doses must be stable for at least 4 weeks prior to Screening blood draw and follow standard recommendations for MTX treatment
  • Subject is judged to be in generally good health as determined by the principal investigator

Exclusion

  • Subject has previous exposure to any systemic anti-TNF therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab
  • Subject has a history of acute inflammatory joint disease of different origin other than RA
  • Subject has been treated with any investigational biologic agents
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant

Key Trial Info

Start Date :

December 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

420 Patients enrolled

Trial Details

Trial ID

NCT00647270

Start Date

December 1 2007

End Date

April 1 2009

Last Update

April 11 2011

Active Locations (86)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 22 (86 locations)

1

Huntsville, Alabama, United States, 35801

2

Tuscaloosa, Alabama, United States, 35406

3

Paradise Valley, Arizona, United States, 85253

4

Hemet, California, United States, 92543

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing | DecenTrialz